Form 8-K - Current report:
SEC Accession No. 0000950170-24-075598
Filing Date
2024-06-20
Accepted
2024-06-20 16:20:08
Documents
11
Period of Report
2024-06-18
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K inzy-20240618.htm   iXBRL 8-K 51185
  Complete submission text file 0000950170-24-075598.txt   168312

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT inzy-20240618.xsd EX-101.SCH 25817
14 EXTRACTED XBRL INSTANCE DOCUMENT inzy-20240618_htm.xml XML 4880
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

EIN.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39397 | Film No.: 241056514
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)